SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Cannabis >

Nemus Bioscience, Inc. (NMUS)

NMUS RSS Feed
Add NMUS Price Alert      Hide Sticky   Hide Intro
Moderator: Paulieme, miracleshappen
Search This Board: 
Last Post: 8/18/2017 12:46:40 AM - Followers: 116 - Board type: Free - Posts Today: 1


 

 NEMUS BIOSCIENCE™ provides pharmaceutical research and development services focused on discovering, developing, and commercializing new chemical entities from a class of chemically diverse compounds. We develop novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the  under the symbol NMUS.

Company Website:  http://www.nemusbioscience.com/home.html

Filings and disclosure with Level 2 quotes:  http://www.otcmarkets.com/stock/NMUS/quote

Contact:

(949) 396-0330
E-MAIL: BRIAN@NEMUSBIO.COM
600 ANTON BLVD, SUITE 1100, COSTA MESA, CA 92626


 

Nemus Bioscience (NMUS) Presentation (47 minutes):  
https://www.youtube.com/watch?v=tYV2PEaj6os

Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 12th, 2016: 
http://s2.q4cdn.com/753474459/files/doc_presentations/2016/Rodman-Conf-September-2016_FINAL.pdf



 


Major press releases:

A Sit Down With Nemus Bioscience; Cannabinoids In Focus Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)  
 

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions -


Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy


Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)

 

Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model

 

Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.


NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 


CANNAINVESTOR Magazine Top 20 Cannabis Stocks 

 

NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference 

 

NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients 

 

NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development 

 

Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN) 

 

NMUS Security Details

Share Structure - as of Feb 1, 2017
Source: otcmarkets.com

Authorized Shares: 236,000,000
Outstanding Shares: 
22,438,163
      - Restricted  13,494,621
    - Unrestricted   8,943,542

           - Float   5,005,713 a/o Mar 23, 2016 
   Par Value 0.001


Transfer Agent: Clear Trust, LLC

NMUS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 08/11/2017 05:05:36 PM
NMUS News: Quarterly Report (10-q) 08/11/2017 05:00:47 PM
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/11/2017 09:10:58 AM
NMUS News: Current Report Filing (8-k) 07/11/2017 09:05:23 AM
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 05/12/2017 04:49:26 PM
PostSubject
#2707   Closewatcher Thank you for that Name AntonChigurh 08/18/17 12:46:40 AM
#2706   Wouldn't get beat up about it. Partnerships for Closewatcher 08/17/17 04:12:17 PM
#2705   You ask tough questions CJ AntonChigurh 08/17/17 02:59:04 PM
#2704   You're right, biotech is a capital intensive industry cjarmstrong 08/17/17 02:30:53 PM
#2703   the 'downtrend' AntonChigurh 08/17/17 01:07:33 PM
#2702   Its par for the course in biotech. This Closewatcher 08/17/17 10:24:24 AM
#2701   I said basic shares, which right now is cjarmstrong 08/17/17 02:28:46 AM
#2700   the Series C guys AntonChigurh 08/17/17 02:26:14 AM
#2699   Were at 40M fully diluted AntonChigurh 08/16/17 03:17:35 PM
#2698   Unfortunately the stock has basically been bearish since cjarmstrong 08/16/17 02:57:51 PM
#2697   There's no volume because there are only about Vinpat 08/16/17 02:56:03 PM
#2696   Not bearish in the slighest. There is literally Closewatcher 08/16/17 10:41:27 AM
#2695   They will never do this If something is PR AntonChigurh 08/15/17 10:55:12 PM
#2694   That is good to hear. Bluesummers 08/15/17 08:08:01 PM
#2693   Well, it's a company in research of a Bluesummers 08/15/17 08:07:36 PM
#2692   NEMUS wake up with a PR. This is Ryan R 08/15/17 06:02:31 PM
#2691   Dr Thomas O'Brien, who has run his own Paulieme 08/15/17 01:36:45 AM
#2690   Correct, they may have a contingency but it cjarmstrong 08/13/17 02:39:20 PM
#2689   the advantages AntonChigurh 08/13/17 12:06:35 AM
#2688   Nemus is still committed to Schneider as per JayZee4 08/12/17 10:21:49 PM
#2687   One would think the funds are coming as Vinpat 08/12/17 07:37:51 PM
#2686   10Q Re Schneider financing AntonChigurh 08/12/17 12:12:27 AM
#2685   I'm going to slap 50 k more into JayZee4 08/11/17 07:45:38 PM
#2684   You didn't per se, but you said "you cjarmstrong 08/11/17 01:15:33 AM
#2683   When did I say cannabinoids are a cure AntonChigurh 08/11/17 12:22:57 AM
#2682   My thoughts exactly. Bluesummers 08/10/17 11:04:49 AM
#2681   Oh wow, NIH sponsored. For a schedule one Bluesummers 08/10/17 11:00:42 AM
#2680   Yeah... pharma. is indeed tough. I wait to Bluesummers 08/10/17 10:59:10 AM
#2679   Nothing yet. Pretty debillitating but it should come through. Closewatcher 08/10/17 10:29:06 AM
#2678   Waiting on pr of this 20m. Any word yet? Doc Strange 08/10/17 09:10:00 AM
#2677   From what I understand, GW is lobbying to cjarmstrong 08/09/17 11:29:34 PM
#2676   There is an established safety profile, but cannabinoids cjarmstrong 08/09/17 11:12:14 PM
#2675   Looking forward to having a beer together when Closewatcher 08/09/17 02:55:00 PM
#2674   NB2 is a CBD analogue AntonChigurh 08/09/17 02:46:29 PM
#2673   NB2111 patent concerns with GW being low energy AntonChigurh 08/09/17 02:44:44 PM
#2672   Yes, I understand that AntonChigurh 08/09/17 02:37:33 PM
#2671   Perhaps the problem is with their permeation enhanced cjarmstrong 08/09/17 01:50:20 PM
#2670   Not unusual, on average only ~33% of drugs cjarmstrong 08/09/17 12:41:42 PM
#2669   Back when I was making up my mind AntonChigurh 08/09/17 01:46:00 AM
#2668   In their 2016 10-K, it mentions that there cjarmstrong 08/08/17 10:53:52 PM
#2667   I haven't looked at it in a couple Vinpat 08/08/17 05:46:33 PM
#2666   What patent issues? cjarmstrong 08/08/17 03:59:48 PM
#2665   Unfortunate, but reiterates the importance of risk assessment. cjarmstrong 08/08/17 03:37:12 PM
#2664   I'd say this news is pretty good. Any Closewatcher 08/08/17 08:22:13 AM
#2663   You're way more knowledgeable on this than I Vinpat 08/07/17 12:59:35 PM
#2662   Listen to this Vinpat guy Im very lucky to AntonChigurh 08/07/17 12:10:01 PM
#2661   Not surprising. The success of their IPO was Vinpat 08/07/17 11:51:59 AM
#2660   This is becoming increasingly painful. Deflated volume, no Ryan R 08/07/17 11:22:50 AM
#2659   https://finance.yahoo.com/news/nemus-bioscience-announces-presentation-cbd-12300 frozenspokes 08/07/17 09:43:01 AM
#2658   ZYNE unfortunately came up short in their Phase Closewatcher 08/07/17 07:46:15 AM
PostSubject